April 2026 in “Frontiers in Medicine” This study analyzed data from the FDA Adverse Event Reporting System and found that enfortumab vedotin, used for urothelial carcinoma, is linked to various cutaneous adverse events, including severe reactions like Stevens–Johnson syndrome, typically occurring early in treatment and predominantly affecting elderly male patients.
April 2026 in “International Journal of Clinical Oncology” This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.
November 2025 in “Frontiers in Pharmacology” This pharmacovigilance study identified 64 drugs linked to hair loss, revealing specific demographic trends and timing patterns, and emphasized the importance of gender-specific monitoring and label updates to better convey real-world risks.
January 2024 in “Archives of pharmacy practice” This study reviews the embryological origins, anatomical and histological structure, and key functions of the skin, emphasizing its protective, sensory, and regulatory roles, as well as the social and psychological impacts of post-lesion changes.
February 2020 in “Oncology Times” This article reviews antibody drug conjugates for cancer treatment, describing their mechanism, recent approvals, and ongoing research efforts, but reports no new clinical results.